
Objectives Cochrane South Africa (CSA) is a Cochrane geographic group established in 1997, aiming to advance the skills and awareness of evidence-based healthcare (EBHC) nationally and regionally through a comprehensive training programme. This project aimed to evaluate the training delivered by CSA from 2021 to 2022.Design We applied the Kirkpatrick model to evaluate the training offered, using a mixed-methods study design that comprised pretraining and post-training online questionnaires and interviews.Setting Online or in-person training events delivered by CSA.Participants Participants included researchers, postgraduate students, health professionals and national and provincial decision-makers attending various training events.Interventions Webinars, courses or workshops on aspects of EBHC.Main outcome measures Reactions to training events, changes in knowledge and behaviour and impact or change in practice.Results Over the course of 1 year, we hosted 19 training events with a total of 985 participants. These included webinars, a protocol development course (PDC) and workshops on the use of systematic reviews. The reaction to training was generally positive though the response rate was low overall (22.6%; 223/985). In terms of learning, participants attending the 'Primer in systematic reviews' workshop increased their knowledge by about 10% after the workshop. Based on seven in-depth interviews with participants of the PDC, they reported applying the knowledge and skills gained to aspects of their work. This included using the knowledge gained to complete their own reviews or to support colleagues also conducting reviews, to shape how they shared information with patients as well as helping to design new primary research.Conclusions The CSA training was well received and seemed to improve participants' knowledge, skills and behaviour. However, cautious interpretation of the findings is needed given the low response rate and reliance on self-reported data. Investing resources in EBHC training, along with regular evaluation, is essential to ensure quality training and increase the number of researchers able to support evidence-informed decision-making.
Objective This systematic review and meta-analysis evaluate the clinical effectiveness, safety and potential risk compensation associated with oral pre-exposure prophylaxis (PrEP) in men who have sex with men (MSM). Methods We systematically searched PubMed, Embase and the Cochrane Library up to 17 September 2025 for randomised controlled trials (RCTs) and observational studies. The primary outcomes were HIV incidence and sexually transmitted infections (STIs). Secondary outcomes included PrEP adherence and adverse events. Meta-analyses used random-effects models, presenting results as relative risks (RRs), risk differences and calculated absolute risk reduction/increase (ARR/ARI) and number needed to treat (NNT) where applicable. Results A total of 21 studies (7 RCTs and 14 observational) with 18 214 participants were included. PrEP use was associated with a 68% RR reduction in HIV acquisition (RR=0.32, 95% CI 0.19 to 0.53; ARR=1.14%, NNT=88). High adherence (≥80%) led to a 78% reduction in HIV risk (RR=0.22, 95% CI 0.09 to 0.54; ARR=1.51%, NNT=66), while lower adherence showed a non-significant 58% reduction (RR=0.42, 95% CI 0.16 to 1.09). Meta-regression indicated a 17% decrease in efficacy per 10% drop in adherence (β = –1.7, p=0.009). No significant differences were found in any adverse events (RR=1.02, 95% CI 0.88 to 1.18) or serious adverse events (RR=0.93, 95% CI 0.68 to 1.28; ARI=−0.00%). There was no significant increase in overall STIs (RR=1.05, 95% CI 0.95 to 1.17; ARI=0.05%) or syphilis incidence (RR=1.11, 95% CI 0.96 to 1.30; ARI=0.11%). Sexual behaviour outcomes were mixed, with no consistent evidence of increased risk-taking. Conclusion PrEP effectively reduces HIV incidence among MSM, particularly when adherence is high, without a significant increase in overall STIs risk. Adherence support and comprehensive sexual health counselling should be integral to PrEP programmes to maximise its effectiveness and mitigate potential risk compensation behaviours. PROSPERO registration number CRD42024593380.
OBJECTIVE:To determine the efficacy of ginger (either stand-alone or as an adjunct treatment) for the treatment and management of migraine headaches. METHODS:We searched PubMed, Embase, CINAHL, PsycINFO, Epistemonikos and Cochrane CENTRAL from inception to 26 March 2025 which was updated on 16 April 2026 and conducted a backwards and forwards citation search of included studies. We included randomised controlled trials (RCTs) that compared the effect of ginger (either stand-alone or as an adjunct) to placebo or usual active control (such as Depakine (valproic acid), amitriptyline or sumatriptan). Two authors independently screened articles, extracted data, assessed risk of bias using the Cochrane Risk of Bias 2 Tool (ROB-2) tool. Primary outcomes included headache severity or pain scores post-treatment, proportion of patients pain free or with pain relief post-treatment, frequency and duration of migraine attacks and migraine-associated symptoms. Random-effects meta-analyses were done and the certainty of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. RESULTS:Eight RCTs involving 594 patients were included. For acute treatments, ginger with ketoprofen compared with placebo with ketoprofen may have little to no difference on headache severity at 2 hours post (mean difference (MD) 1.27 lower, 95% CI 1.46 lower to 1.08 lower; 1 study, 60 participants; low certainty evidence). It was very uncertain if ginger combined with feverfew versus placebo or ginger alone compared with sumatriptan improved proportions of those with pain relief, pain free or the mean headache severity at 2 hours post. For preventative treatment, ginger in addition to an active drug compared with the same active drug with or without placebo, may result in an important reduction in headache pain severity at 3 months (pooled MD -3.18, 95% CI -3.94 to -2.42; 2 studies, 183 participants; low certainty evidence). However, it was very uncertain if ginger combined with herbs compared with active drugs of both Depakine and amitriptyline lowered headache frequency, duration or headache severity at 3 months. The overall certainty of evidence for all outcome measures ranged from low to very low. CONCLUSIONS:The volume of the existing evidence is limited and combined with either a low or very low certainty of evidence, it is currently too uncertain if ginger is effective either as an acute or preventative treatment. Therefore, additional acute and preventative trials are required to help raise the certainty of evidence. TRIAL REGISTRATION NUMBER:https://www.crd.york.ac.uk/PROSPERO/view/CRD420251025768.
Understanding the risks associated with healthcare interventions is essential for clinical decision-making and for the regulatory evaluation of new drugs. Yet, safety analyses in randomised controlled trials are often conducted without clearly specifying (a) the estimand of interest in the presence of intercurrent events (IEs) (ie, events such as treatment discontinuation or use of rescue medication that occur after randomisation and complicate outcome interpretation) or (b) the estimand implicitly targeted by the statistical estimator used in the analysis. This lack of clarity produces ambiguous results and complicates their interpretation.This paper provides practical guidance on applying the estimand framework from the ICH E9(R1) addendum to safety outcomes in phase III randomised trials conducted for regulatory submissions. We describe how IEs influence the interpretation of treatment effects in safety assessment and how commonly used safety estimators align with different estimands, making explicit both the clinical question and the assumptions required to estimate it.Although the primary emphasis is on regulatory trials, where these decisions are especially consequential, the principles outlined are equally applicable to other randomised interventions and non-interventional studies. As safety results from pivotal regulatory trials are increasingly published using estimand terminology, these concepts are essential not only for researchers such as statisticians, clinicians and regulators involved in clinical development but also for clinicians who prescribe newly approved drugs and need to interpret safety results communicated using estimand terminology to inform their clinical decision-making. This paper aims to make these concepts accessible to a broader medical audience.